financetom
SLGN
financetom
/
Consumer Discretionary
/
SLGN
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Silgan Holdings Inc.SLGN
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Silgan Holdings Inc., together with its subsidiaries, manufactures and sells rigid packaging solutions for consumer goods products in the United States and internationally.

It operates through three segments: Dispensing and Specialty Closures, Metal Containers, and Custom Containers.

The Dispensing and Specialty Closures segment offers a range of metal and plastic closures, and dispensing systems for food, beverage, health care, garden, home, personal care, and beauty products, as well as capping/sealing equipment and detection systems.

The Metal Containers segment manufactures and sells steel and aluminum containers for food products, such as pet food, vegetables, soups, proteins, tomato based products, fruits, and other miscellaneous food products, as well as general line metal containers primarily for chemicals.

The Custom Containers segment manufactures and sells custom designed and stock plastic containers for use in personal care and health care; food and beverage; household and industrial chemical; pharmaceutical; pet food and care; agricultural; automotive; and marine chemical products.

This segment also provides plastic thermoformed barrier and non-barrier bowls, and trays for food products, such as soups, other ready-to-eat meals, and pet food products; and plastic closures, caps, sifters, and fitments, as well as thermoformed tubs for food, household, and personal care products.

The company markets its products primarily through direct sales force, as well as through a network of distributors, and an online shopping catalog.

The company was founded in 1987 and is headquartered in Stamford, Connecticut.

Latest News >
Walmart Continues Market Share Gains Despite Slower Q4 Growth, UBS Says
Walmart Continues Market Share Gains Despite Slower Q4 Growth, UBS Says
Feb 21, 2025
11:13 AM EST, 02/21/2025 (MT Newswires) -- Walmart ( WMT ) continues to gain market share and expand its alternative revenue streams despite a slight slowdown in sales growth during Q4, UBS Securities said in a report emailed Friday. Walmart ( WMT ) reported fiscal Q4 adjusted earnings Thursday of $0.66 per diluted share, up from $0.60 a year ago,...
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
Feb 21, 2025
11:09 AM EST, 02/21/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were slightly higher late Friday morning, edging 0.11% higher to 1,405.16 on the S&P Europe Select ADR Index, which is flat for the week. From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk ( NVO ) and accommodations booking site...
BTC Rejected at $100K After $1.5B Bybit Hack, SEC to Halt Coinbase Lawsuit: Your Weekly Crypto Recap
BTC Rejected at $100K After $1.5B Bybit Hack, SEC to Halt Coinbase Lawsuit: Your Weekly Crypto Recap
Feb 21, 2025
It was a relatively slow and quiet uneventful week for the cryptocurrency markets but Friday turned the tables around with some big news. But before we dive into the major developments that took place earlier today, lets focus on the price movements over the past week. Recall that the largest digital asset spiked to $99,000 last Friday where it was...
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study
Feb 21, 2025
11:10 AM EST, 02/21/2025 (MT Newswires) -- Estrella Immunopharma ( ESLA ) said Friday it has completed the first dose group in its ongoing phase I/II clinical trial evaluating EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Based on preliminary data, no dose-limiting toxicities or serious adverse events related to treatment were observed in the group, with tumor response...
Copyright 2023-2025 - www.financetom.com All Rights Reserved